Attributes | Values |
---|
rdf:type
| |
description
| - wetenschappelijk artikel (nl)
- artículu científicu espublizáu en xunu de 2019 (ast)
- scientific article published on 17 June 2019 (en)
- наукова стаття, опублікована 17 червня 2019 (uk)
|
publication date
| |
publication date
| |
author name string
| |
author name string
| |
rdfs:label
| - Response to: 'response to: 'Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis' by Sabbagh S et al' by Yang et al (en)
- Response to: 'response to: 'Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis' by Sabbagh S et al' by Yang et al (nl)
|
skos:prefLabel
| - Response to: 'response to: 'Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis' by Sabbagh S et al' by Yang et al (en)
- Response to: 'response to: 'Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis' by Sabbagh S et al' by Yang et al (nl)
|
name
| - Response to: 'response to: 'Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis' by Sabbagh S et al' by Yang et al (en)
- Response to: 'response to: 'Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis' by Sabbagh S et al' by Yang et al (nl)
|
author
| |
author
| |
title
| |
title
| - Response to: 'response to: 'Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis' by Sabbagh S et al' by Yang et al (en)
|
instance of
| |
instance of
| |
main subject
| |
main subject
| |
PubMed ID
| |
PubMed ID
| |
PubMed ID
| |
published in
| |
published in
| |
DOI
| |
DOI
| |
DOI
| - 10.1136/ANNRHEUMDIS-2019-215693
|
is about
of | |